1.
J Clin Psychiatry
; 63 Suppl 1: 10-7, 2002.
Article
in English
| MEDLINE
| ID: mdl-11890560
ABSTRACT
The past decade has witnessed the introduction of a diverse group of antidepressants from a variety of distinct chemical classes, each with their own specificity for neurochemical transmitters, receptors, and cytochrome P450 isozymes. This review focuses on nefazodone, a distinct antidepressant with efficacy for the treatment of depression with depression-related anxiety symptoms, an established tolerability profile, and a multimodal mechanism of action. Relevant pharmacologic and pharmacodynamic effects are summarized that support nefazodone as an attractive choice for both the short- and long-term treatment of depression.
Subject(s)
Antidepressive Agents, Second-Generation/pharmacology , Depressive Disorder/drug therapy , Triazoles/pharmacology , Antidepressive Agents, Second-Generation/pharmacokinetics , Antidepressive Agents, Second-Generation/therapeutic use , Anxiety Disorders/drug therapy , Drug Interactions , Humans , Piperazines , Receptors, Serotonin/drug effects , Serotonin Antagonists/pharmacokinetics , Serotonin Antagonists/pharmacology , Serotonin Antagonists/therapeutic use , Selective Serotonin Reuptake Inhibitors/pharmacology , Sleep/drug effects , Sleep/physiology , Triazoles/pharmacokinetics , Triazoles/therapeutic use
2.
J Clin Psychiatry
; 63 Suppl 1: 3-9, 2002.
Article
in English
| MEDLINE
| ID: mdl-11890562